388626-12-8 Usage
Description
TRKA INHIBITOR is an oxindole compound that acts as a cell-permeable, reversible, potent, and highly selective inhibitor of TrkA.
Uses
Used in Pharmaceutical Industry:
TRKA INHIBITOR is used as a therapeutic agent for targeting the TrkA receptor, which is involved in various cellular processes, including cell growth, differentiation, and survival. By inhibiting TrkA, TRKA INHIBITOR can potentially be used in the treatment of various diseases, such as cancer, neurodegenerative disorders, and inflammatory conditions.
Used in Cancer Research:
TRKA INHIBITOR is used as a research tool for studying the role of TrkA in cancer development and progression. It can help researchers understand the molecular mechanisms underlying TrkA-mediated signaling pathways and identify potential therapeutic targets for cancer treatment.
Used in Drug Development:
TRKA INHIBITOR is used as a lead compound in the development of new drugs targeting the TrkA receptor. Its potent and selective inhibition of TrkA makes it a promising candidate for further optimization and development into a clinically relevant drug for the treatment of TrkA-related diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 388626-12-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,8,8,6,2 and 6 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 388626-12:
(8*3)+(7*8)+(6*8)+(5*6)+(4*2)+(3*6)+(2*1)+(1*2)=188
188 % 10 = 8
So 388626-12-8 is a valid CAS Registry Number.
388626-12-8Relevant articles and documents
Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis
Bramson,Holmes,Hunter,Lackey,Lovejoy,Luzzio,Montana,Rocque,Rusnak,Shewchuk,Veal,Corona,Walker,Kuyper,Davis,Dickerson,Edelstein,Frye,Gampe Jr.,Harris,Hassell
, p. 4339 - 4358 (2007/10/03)
Two closely related classes of oxindole-based compounds, 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2). The initial lead compound was prepared as a homologue of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor. Crystallographic analysis of the lead compound bound to CDK2 provided the basis for analogue design. A semiautomated method of ligand docking was used to select compounds for synthesis, and a number of compounds with low nanomolar inhibitory activity versus CDK2 were identified. Enzyme binding determinants for several analogues were evaluated by X-ray crystallography. Compounds in this series inhibited CDK2 with a potency ～10-fold greater than that for CDK1. Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.
